SNY Sanofi SA

  • STOCK
  • SNY
  • Price as of: Sep 30, 12:33 PM EDT
  • $38.14
  • +$0.31
  • +0.8%
  • Industry
  • Drug manufacturers - major
Share

SNY Stock Dividend Data

Add SNY to Watchlist
  • Dividend Yield
    4.36% Healthcare Average 0.95%
  • Annualized Payout
    $1.66 Paid Annual
  • Payout Ratio
    54.9% EPS $3.03
  • Dividend Growth
    No Payout Increase Last Year
  • Get SNY DARS™ Rating

Looking to buy or sell SNY?

Buy Now
Sell Now
Upcoming Dividend Payouts

SNY Upcoming Dividend Payouts

SNY has not yet officially announced its next dividend payout.
DARS Rating™ Breakdown

Dividend.com DARS Rating™ Breakdown for SNY

Sign Up
Metric SNY Rank SNY Avg Ranking Notes
Relative Strength 1 year return is at par with Benchmark/Peers/Broader Market/Analyst Expectations
Overall Yield Attractiveness Yield is better than Benchmark/Peers/Broader Market/Analyst Expectations
Dividend Reliability Payout ratio is considerably higher than industry average and peers
Dividend Uptrend Dividends are above average, growing as per Benchmark/Peers/Broader Market/Analyst Expectations
Earnings Growth EPS growth is below Benchmark/Peers/Broader Market/Analyst Expectations
DARS Rating Sign Up For DARS Ratings
Growth History

SNY Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
-1.6% -15.7% No Payout Increase Last Year
Reveal More Dividend Growth History for SNY
Historical Annual Dividend Data & Growth

SNY Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
$1.6093 2015 -15.7%
$1.9098 2014 6.5%
Historical Dividend Data

SNY Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$1.6633 2016-05-05 2016-05-09 2016-06-01 Unknown Regular Annual
$1.6093 2015-05-06 2015-05-08 2015-06-02 Unknown Regular Annual
$1.9098 2014-05-07 2014-05-09 2014-06-05 Unknown Regular Annual
$1.7925 2013-05-06 2013-05-08 2013-06-05 Unknown Regular Annual
$1.6892 2012-05-07 2012-05-09 2012-05-30 Unknown Regular Annual
$1.3225 2011-05-11 2011-05-13 2011-06-24 Unknown Regular Annual
$1.4650 2010-05-17 2010-05-19 2010-06-14 Unknown Regular Annual
$1.4391 2009-04-20 2009-04-22 2009-05-29 Unknown Regular Annual
$1.6254 2008-05-16 2008-05-20 2008-06-13 Unknown Regular Annual
$1.1675 2007-06-04 2007-06-06 2007-07-03 Unknown Regular Annual
$0.8181 2006-06-02 2006-06-06 2006-07-03 Unknown Regular Annual
$0.6241 2005-06-02 2005-06-06 2005-07-01 Unknown Unknown unknown
$0.0231 2004-09-27 2004-09-29 2004-10-05 Unknown Unknown unknown
$0.4931 2004-04-30 2004-05-04 2004-06-01 Unknown Unknown unknown
$0.4162 2003-05-28 2003-05-30 2003-06-26 Yes Unknown unknown
$0.0650 1999-03-01 1999-03-11 1999-03-15 1999-03-31 Unknown Regular Quarter
$0.0650 1998-12-02 1998-12-11 1998-12-15 1998-12-31 Unknown Regular Quarter
$0.0650 1998-09-02 1998-09-11 1998-09-15 1998-09-30 Unknown Regular Quarter
$0.0650 1998-06-02 1998-06-11 1998-06-15 1998-06-30 Unknown Regular Quarter
$0.0650 1998-03-02 1998-03-11 1998-03-13 1998-03-31 Unknown Regular Quarter
$0.0650 1997-12-02 1997-12-11 1997-12-15 1997-12-31 Unknown Regular Quarter
$0.0650 1997-09-02 1997-09-11 1997-09-15 1997-09-30 Unknown Regular Quarter
$0.0650 1997-06-02 1997-06-11 1997-06-13 1997-06-30 Unknown Regular Quarter
$0.0650 1997-03-06 1997-03-12 1997-03-14 1997-03-31 Unknown Regular Quarter
$0.0650 1996-12-02 1996-12-11 1996-12-13 1996-12-31 Unknown Regular Quarter
$0.0650 1996-08-30 1996-09-11 1996-09-13 1996-09-30 Unknown Regular Quarter
$0.0650 1996-06-03 1996-06-12 1996-06-15 1996-06-28 Unknown Regular Quarter
$0.0650 1996-03-04 1996-03-13 1996-03-15 1996-03-29 Unknown Regular Quarter
$0.0650 1995-12-01 1995-12-13 1995-12-15 1995-12-29 Unknown Regular Quarter
$0.0650 1995-09-01 1995-09-13 1995-09-15 1995-09-29 Unknown Regular Quarter
$0.0650 1995-06-02 1995-06-13 1995-06-15 1995-06-30 Unknown Regular Quarter
$0.0650 1995-03-03 1995-03-09 1995-03-15 1995-03-31 Unknown Regular Quarter
$0.0650 1994-12-02 1994-12-09 1994-12-15 1994-12-30 Unknown Regular Quarter
$0.0650 1994-09-02 1994-09-09 1994-09-15 1994-09-30 Unknown Regular Quarter
$0.0600 1994-06-06 1994-06-09 1994-06-15 1994-06-30 Unknown Regular Quarter
$0.0600 1994-03-03 1994-03-09 1994-03-15 1994-03-31 Unknown Regular Quarter
$0.0600 1993-12-06 1993-12-09 1993-12-15 1993-12-31 Unknown Regular Quarter
$0.0600 1993-09-03 1993-09-09 1993-09-15 1993-09-30 Unknown Regular Quarter
$0.0500 1993-06-03 1993-06-09 1993-06-15 1993-06-30 Unknown Regular Quarter
$0.0500 1993-03-03 1993-03-09 1993-03-15 1993-03-31 Unknown Regular Quarter
Company Profile

SNY Company Profile

Exchange: NYSE
Sector: Healthcare

Sanofi (SNY), formerly known as Sanofi-Aventis, engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines. The company was founded in 1970 and is headquartered in Paris, France.

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks
News

Sanofi SA News

  • Before Wednesday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the most important analyst commentary for investors.

  • A number of big-name dividend stocks were subject to analyst moves before the opening bell today. We highlight the most important changes, along with analyst commentary below.

  • One of the biggest misconceptions in investing is that domestic markets are somehow safer and better than investing abroad. For whatever reason, many of us believe that owning stocks and bonds in the U.S. is the best way to go. As a result, this...

  • Excuse the cheesy title, but it's true. For investors looking to put capital to work in today's environment, the domestic equity landscape may...
  • Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
  • Before the opening bell on Tuesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
  • Sanofi Reports Positive Test Results for New Flu Treatment (SNY)

    Early on Monday, pharmaceutical company Sanofi SA (SNY) announced that it saw topline results in its large-scale, multi-center efficacy trial of Fluzone High-Dose Influenza Virus Vaccine in people 65 years of age and older, relative to the standard dose of Fluzone in preventing the flu. In other words, the tests showed that Fluzone High-Dose does a better job at preventing the flu among older people than a standard dose of Fluzone. Sanofi Pasteur, the company's vaccines division, expects to submit the full clinical study to the FDA for review by early 2014. "We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine compared to Fluzone vaccine in preventing influenza in older adults," said David P. Greenberg, M.D., Vice President, U.S. Scientific and Medical Affairs, Sanofi Pasteur. "This efficacy trial complements the previous evidence of superior immune responses for Fluzone High-Dose vaccine compared to Fluzone vaccine and reaffirms the Phase III safety data in this population that were the basis for FDA licensure of Fluzone High-Dose vaccine in 2009." Sanofi SA shares were up 54 cents, or 1.07%, during pre-market trading on Monday. The stock is up 6.59% year-to-date. The Bottom Line Shares of Sanofi (SNY) offer a dividend yield of 3.68% based on Friday's closing price of $50.50 and the company's annualized dividend payout of $1.86 per share. Sanofi SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Advance Auto Parts...
  • Sanofi-Aventis Makes Hostile Bid for Genzyme (SNY)

    French pharmaceutical giant Sanofi-Aventis SA (SNY) on Monday announced it has made a hostile takeover bid for biotech company Genzyme Corp. (GENZ). Sanofi's tender offer, which was made directly to shareholders of Genzyme, is for $69 per common share. The total value of such a transaction is around $18.5 billion. Genzyme has until December 10, 2010, to either accept or decline the offer, as it will expire on that date. The offer represents a 38% premium Genzyme's July 1 closing price, but is actually lower than GENZ's Friday closing price of $70.88. Genzyme's shares have rocketed higher in recent months, since the initial takeover rumors began. Sanofi-Aventis shares were mostly flat in premarket trading Monday. The Bottom Line We had removed shares of SNY from our recommended list back on Apr.27, when the stock was trading at $36.10. The company has a 4.29% dividend yield, based on Friday's closing stock price of $33.12 The stock has technical support in the $30 price area. If the shares can firm up, we see overhead resistance around the $36-$38 price levels. We would remain on the sidelines for now. Sanofi-Aventis SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Sanofi-Aventis Offers $18.5 Billion for Genzyme (SNY, GENZ)

    French pharma giant Sanofi-Aventis SA (SNY) on Monday officially announced an $18.5 billion takeover bid for biotech company Genzyme Corporation (GENZ). Sanofi said it first made the offer on July 29, which Genzyme quickly refused as undervaluing the company. Now, Sanofi is putting the pressure on Genzyme to head to the negotiating table by going public with the bid. "We feel we are left with no choice but to take our compelling proposal directly to your shareholders by making its terms public," said Sanofi CEO Christopher Viehbacher in a letter to Genzyme management. In response, Genzyme CEO Henri Termeer said "[the offer] provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board." Thus far, Sanofi claims that Genzyme has been "unwilling even to meet" to discuss a possible deal. The $69 per-share cash offer represented a 38% premium over GENZ's July 1 closing price. Sanofi-Aventis shares rose 16 cents, or +0.6%, in premarket trading Monday. The Bottom Line We had removed shares of SNY from our recommended list back on Apr.27, when the stock was trading at $36.10. The company has a 4.91% dividend yield, based on last night's closing stock price of $28.92. The stock has technical support in the $26 price area. If the shares can firm up, we see overhead resistance around the $32 price level. We would remain on the sidelines for now. Sanofi-Aventis SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story